Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics.
Gao Y, Kabotyanski EB, Shepherd JH, Villegas E, Acosta D, Hamor C, Sun T, Montmeyor-Garcia C, He X, Dobrolecki LE, Westbrook TF, Lewis MT, Hilsenbeck SG, Zhang XH, Perou CM, Rosen JM. Gao Y, et al. Among authors: hamor c. Cancer Res Commun. 2021 Dec;1(3):178-193. doi: 10.1158/2767-9764.crc-21-0106. Epub 2021 Dec 27. Cancer Res Commun. 2021. PMID: 35156101 Free PMC article.
Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer.
Singh S, Lee N, Pedroza DA, Bado IL, Hamor C, Zhang L, Aguirre S, Hu J, Shen Y, Xu Y, Gao Y, Zhao N, Chen SH, Wan YW, Liu Z, Chang JT, Hollern D, Perou CM, Zhang XHF, Rosen JM. Singh S, et al. Among authors: hamor c. Cancer Res. 2022 Jun 15;82(12):2281-2297. doi: 10.1158/0008-5472.CAN-21-3714. Cancer Res. 2022. PMID: 35442423 Free PMC article.
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM. Zhao N, et al. Among authors: hamor c. J Clin Invest. 2023 Dec 15;133(24):e172503. doi: 10.1172/JCI172503. J Clin Invest. 2023. PMID: 37874652 Free PMC article.
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM. Zhao N, et al. Among authors: hamor c. bioRxiv [Preprint]. 2023 Sep 28:2023.09.28.559973. doi: 10.1101/2023.09.28.559973. bioRxiv. 2023. PMID: 37808840 Free PMC article. Updated. Preprint.